<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02580448</url>
  </required_header>
  <id_info>
    <org_study_id>INO-VT-464-CL-006</org_study_id>
    <nct_id>NCT02580448</nct_id>
  </id_info>
  <brief_title>CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)</brief_title>
  <acronym>CLARITY-01</acronym>
  <official_title>A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innocrin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innocrin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical study is to determine the safety, pharmacokinetics,
      pharmacodynamics and efficacy and activity of seviteronel, a lyase-selective inhibitor of
      CYP17, in patients with advanced breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase 1/2 study of seviteronel in subjects with TNBC or ER +/HER2
      normal unresectable locally advanced breast cancer. Only women will be enrolled in Phase 1
      and both men and women enrolled into their respective cohorts in Phase 2. There will be a
      dose confirmation Phase 1 portion of the study to establish the recommended Phase 2 dose
      (RP2D) for women with breast cancer using a non-stratified, combined cohort of women with
      TNBC or ER+ BC. Cohort expansion will occur in Phase 2 at the RP2D confirmed/established in
      Phase 1 using separate TNBC and ER+ cohorts. The Phase 2 portion of the study is divided into
      three parallel cohorts:

      Cohort 1: Female TNBC Subjects Cohort 2: Female ER+ Subjects Cohort 3: Male ER+ BC or TNBC
      Subjects
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate efficacy of seviteronel as measured by clinical benefit rate at 16 weeks (CBR16) for female subjects with TNBC.</measure>
    <time_frame>Duration of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate efficacy of seviteronel as measured by clinical benefit rate at 24 weeks (CBR24) for female subjects with ER+ BC.</measure>
    <time_frame>Duration of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate efficacy of seviteronel as measured by CBR16 for all male BC subjects.</measure>
    <time_frame>Duration of Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe the pharmacokinetics of seviteronel</measure>
    <time_frame>At least monthly over the first eight 28-day cycles</time_frame>
    <description>Area under the curve concentration verses time curve and Peak Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate efficacy of seviteronel as measured by the overall response rate (ORR) based on RECIST 1.1</measure>
    <time_frame>At least monthly over the first eight 28-day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate efficacy of seviteronel as measured by progression-free survival (PFS)</measure>
    <time_frame>At least monthly over the first eight 28-day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the safety profile of seviteronel</measure>
    <time_frame>Duration of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the safety profile of seviteronel with or without concurrent glucocorticoid administration</measure>
    <time_frame>Duration of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the CBR16 with or without concurrent glucocorticoid administration for female subjects with TNBC</measure>
    <time_frame>Duration of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Cancer of the Breast</condition>
  <condition>Breast Cancer</condition>
  <condition>Advanced Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Male Breast Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>ER+ Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Female Triple Negative Breast Cancer Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNBC Patients - Enrollment is complete in this cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female Estrogen Receptor (+) Breast Cancer Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female ER(+) BC Patients - Enrollment is complete in this cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male Breast Cancer Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Locally advanced or metastatic males with BC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seviteronel</intervention_name>
    <description>Seviteronel given daily with evening meal in 28 day cycles</description>
    <arm_group_label>Female Triple Negative Breast Cancer Patients</arm_group_label>
    <arm_group_label>Female Estrogen Receptor (+) Breast Cancer Patients</arm_group_label>
    <arm_group_label>Male Breast Cancer Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Each subject eligible to participate in this study must meet or have all the following
        criteria:

          1. Is 18 years of age or older.

          2. Can provide written informed consent or have their legal representatives provide
             written informed consent

          3. Have documented histological or cytological evidence of invasive cancer of the breast,
             defined by one of the following:

               -  ER+ breast cancer, defined as positive if ≥ 1% by IHC and HER2 normal, defined as
                  IHC 0-1+ or IHC 2+(and FISH&lt;2), or FISH &lt; 2.0

               -  TNBC, defined as ER-/PgR- if 0 % by IHC and HER2 normal, defined as IHC 0-1+ or
                  IHC 2+(and FISH&lt;2), or FISH &lt; 2.0

          4. ECOG PS of 0 or 1 for Females, 0, 1, or 2 for Males.

          5. Undergoing or willing to undergo gonadal suppression:

               -  Female subjects with ER+/HER2 normal tumors must be post-menopausal defined by
                  local practice. Ovarian suppression with a LHRH analogue to achieve cessation of
                  regular menses is allowed on study

               -  Male subjects must be undergoing or willing to undergo gonadal suppression whilst
                  on study drug and continue with the LHRH analogue for the duration of the study

          6. Subjects must have adequate hematopoietic function as evidenced by:

               -  WBC ≥ 3,000/μl

               -  ANC ≥ 1,500/μl

               -  Platelet count ≥ 100,000/μl

               -  HGB ≥ 9 g/dl and not transfusion dependent

          7. Adequate liver function, including all the following:

               -  Total serum bilirubin ≤2.0 x ULN unless the subject has documented Gilbert
                  syndrome;

               -  Aspartate and alanine aminotransferase (AST &amp; ALT) ≤3.0 x ULN or ≤5.0 x ULN if
                  subject has liver metastasis;

               -  Alkaline phosphatase ≤3.0 x ULN or ≤5 x ULN in case of bone metastasis and/or
                  hepatic metastasis

          8. Subjects must have adequate renal function as evidenced by a serum creatinine of ≤ 2.0
             mg/dl.

          9. Potassium (K+) ≥3.5 mEq/L

         10. Women of child-bearing potential must have a negative serum or urine pregnancy test
             within 72 hours of C1D1.

         11. Women of child-bearing potential and male subjects with a female partner of
             childbearing potential must use 2 acceptable methods of birth control (one of which
             must include a condom as a barrier method of contraception) starting at Screening and
             continuing throughout the study period and for 3 months after final study drug
             administration i. Two acceptable forms of birth control include:

        1. Condom (barrier method of contraception), and 2. One of the following:

          1. Oral, injected or implanted hormonal contraception

          2. Placement of an intrauterine device (IUD) or intrauterine system (ISU)

          3. Additional barrier methods of contraception: Occlusive cap (diaphragm or
             cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.

          4. Vasectomy or surgical castration ≥ 6 months prior to Screening. 12. Able to swallow
             study medication 13. Able to comply with study requirements

        Exclusion Criteria

          1. Received any investigational agent within 5 half-lives of the agent in question; if
             the half-life is not known, ≤ 28 days of C1D1.

          2. Received palliative radiotherapy ≤ 2 weeks of C1D1

          3. Received any other therapeutic treatment for breast cancer ≤ 2 weeks of C1D1, except
             for hormonal therapies.

          4. Symptomatic CNS metastases.

          5. History of another invasive malignancy ≤ 3 years of C1D1.

          6. A QTcF interval &gt;470 msec on the Screening ECG. If the ECG QTcF interval is &gt;470 msec,
             then the mean QTcF of a triplicate ECGs can be used and if the mean is &lt;470 msec, the
             subject may be enrolled.

          7. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular
             fibrillation, atrial fibrillation with rapid ventricular response, torsades de
             pointes, second degree or third degree atrioventricular heart block without a
             permanent pacemaker in place).

          8. Class III or IV Congestive Heart Failure (CHF) as defined by the New York Heart
             Association (NYHA) functional classification system within the previous 6 months

          9. Initiated a bone modifying agent (e.g. denosumab) ≤ 28 days of C1D1.

         10. Any medical condition that could preclude their participation in the study, pose an
             undue medical hazard, or which could interfere with the interpretation of the study
             results.

         11. A history of seizure ≤ 2 years of C1D1 or those who require prophylactic anti-seizure
             medications.

         12. A history of loss of consciousness or transient ischemic attack ≤ 12 months before
             C1D1.

         13. Known active HIV, Hepatitis B, or Hepatitis C infections.

         14. Known or suspected hypersensitivity to seviteronel, or any components of the
             formulation.

         15. Any other condition which in the opinion of the investigator would preclude
             participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victoria Brown, BS</last_name>
    <role>Study Chair</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victoria Brown, BS</last_name>
    <phone>919-808-1427</phone>
    <email>vbrown@innocrinpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Franklin, BS</last_name>
    <phone>919-695-9493</phone>
    <email>lfranklin@innocrinpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wallace Tumor Institute- University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly LaMaster, RN</last_name>
      <phone>205-975-0306</phone>
      <email>lamaster@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Christos Vaklavas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Scheiner</last_name>
      <phone>720-848-0719</phone>
      <email>jonathan.scheiner@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Elias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Speyer</last_name>
      <email>sue.speyer@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Ling Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cara O'Keefe, BS</last_name>
      <phone>239-274-8200</phone>
      <phone_ext>0125</phone_ext>
      <email>cokeefe@FLCancer.com</email>
    </contact>
    <investigator>
      <last_name>Fadi Kayali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists- North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marsha Ketcham</last_name>
      <email>mketcham@nebraskacancer.com</email>
    </contact>
    <investigator>
      <last_name>Gail Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Wall, RN</last_name>
      <phone>706-721-4430</phone>
      <email>swall@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Jigarkumar Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI - HCA Midwest Division</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>61432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zac Cliffford</last_name>
      <phone>816-276-4459</phone>
      <email>zachary.clifford@hcamidwest.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Feedback</last_name>
      <phone>816-276-4227</phone>
      <email>juennifer.feedback@hcamidwest.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stephanie Graff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital / James Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belma Kantardzic</last_name>
      <phone>502-562-4356</phone>
      <email>belma.kantardzic@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Riley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Johannesen</last_name>
      <email>Margaret.Johannesen@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Cheryl Aylesworth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shealagh Clark</last_name>
      <phone>617-643-4759</phone>
      <email>sclark31@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Aditya Bardia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheryl Morgan</last_name>
      <phone>734-615-0669</phone>
      <email>shermorg@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Catherine Van Poznak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trish Vallieres</last_name>
      <phone>313-916-2438</phone>
      <email>PVALLIE9@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Haythem Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerri Anderson</last_name>
      <email>ander258@umn.edu</email>
    </contact>
    <investigator>
      <last_name>David Potter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Network/Oncology Associates PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marsha Ketcham</last_name>
      <email>mketcham@nebraskacancer.com</email>
    </contact>
    <investigator>
      <last_name>Geetha Palaniappan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aretha DiSalvo, RN</last_name>
      <phone>551-996-8258</phone>
      <email>Aretha.DiSalvo@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Deena Graham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Strano</last_name>
      <phone>631-751-3000</phone>
      <phone_ext>170</phone_ext>
      <email>mstrano@nshoa.com</email>
    </contact>
    <investigator>
      <last_name>Noshir DaCosta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vidhisha Mulani</last_name>
      <email>mulaniv@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Zola Sundar, MPH, CCRP</last_name>
      <phone>646 888-5345</phone>
      <email>sookhooz@mskcc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Tiffany A. Traina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Dunn</last_name>
      <phone>984-974-8675</phone>
      <email>charlotte_dunn@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Carey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center - Oncology Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Griswald</last_name>
    </contact>
    <contact_backup>
      <email>dgriswell@novanthealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ayla Kessler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheryl Cummings, RN, OCN</last_name>
      <phone>919-613-4579</phone>
      <email>sheryl.cummings@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>April Pennix</last_name>
      <email>april.pennix@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kelly Marcom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne O'Malley</last_name>
      <email>aomalley@gabrilcancercenter.com</email>
    </contact>
    <contact_backup>
      <last_name>, BS</last_name>
    </contact_backup>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Hagen</last_name>
      <phone>513-751-2273</phone>
      <phone_ext>12902</phone_ext>
      <email>brittany.hagen@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Vollmer</last_name>
      <phone>513-751-2273</phone>
      <phone_ext>12901</phone_ext>
      <email>ashley.vollmer@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Suzanne Partridge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robyn Patrick</last_name>
      <phone>614-293-0194</phone>
      <email>robyn.patrick@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Bhuvaneswari Ramaswamy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Gruenberg</last_name>
      <phone>614-685-6046</phone>
      <email>erika-gruenberg@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Wajeeja Razaq, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Stitzel</last_name>
      <email>stitzelw@oshu.edu</email>
    </contact>
    <investigator>
      <last_name>Jacqueline Vuky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology and Oncology Associates</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandi Rischer</last_name>
      <email>Brandi.Risher@choasc.com</email>
    </contact>
    <investigator>
      <last_name>David Ellison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Precision Cancer Research/Brig Center for Cancer Care and Survivorship, LLC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Simcox</last_name>
      <email>ksimcox@precisioncancerresearch.com</email>
    </contact>
    <investigator>
      <last_name>Raymond Brig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI Tenessee Oncology Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marsha Dunn</last_name>
      <phone>615-329-7234</phone>
      <email>Marsha.Dunn@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Denise Yardley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrell Martinez</last_name>
      <phone>214-658-1946</phone>
      <email>tmartinez@marycrowley.org</email>
    </contact>
    <investigator>
      <last_name>Minal Barve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Clark</last_name>
      <email>valerie.clark@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara Haley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders (Fort Worth)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna Phillips</last_name>
      <phone>817-759-7000</phone>
      <email>dphillips@txcc.com</email>
    </contact>
    <investigator>
      <last_name>Robyn Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>US Oncology</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76177</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Stephenson</last_name>
      <email>erin.stephenson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Cynthia Osborne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brady Gamble</last_name>
      <phone>801-585-0550</phone>
      <email>Brady.Gamble@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Lynn Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Sawyer</last_name>
      <phone>757-459-9217</phone>
      <email>brittany.sawyer@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Danso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Breast</keyword>
  <keyword>Advanced Breast Cancer</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>CYP17</keyword>
  <keyword>Male Breast Cancer</keyword>
  <keyword>Triple Negative Cancer</keyword>
  <keyword>ER+ Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

